A Community-Based Transcriptomics Classification and Nomenclature Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genetic Susceptibility for Cow's Milk Allergy in Dutch Children
Henneman et al. Clin Transl Allergy (2016) 6:7 DOI 10.1186/s13601-016-0096-9 Clinical and Translational Allergy RESEARCH Open Access Genetic susceptibility for cow’s milk allergy in Dutch children: the start of the allergic march? Peter Henneman1*†, Nicole C. M. Petrus2†, Andrea Venema1, Femke van Sinderen1, Karin van der Lip1, Raoul C. Hennekam1, Marcel Mannens1† and Aline B. Sprikkelman2† Abstract Background: Cow’s milk allergy (CMA) is the most common allergic disease in infancy. It is not clear, whether infants with CMA have an increased risk of developing other allergic diseases later in life, the so-called “allergic march”. We aimed to detect genetic associations of CMA using reported single nucleotide polymorphisms (SNP) in other allergic diseases and genetic mutations within the filaggrin (FLG) gene. Both to investigate possible causes of CMA, which also suggests an “allergic march”. Methods: Thirty children from the Dutch EuroPrevall birth cohort study with CMA in infancy and twenty-three healthy controls were studied. Six candidate SNPs were selected (minor allele frequency 10–50 % combined with a large effect) based on the literature. Thirteen FLG candidate mutations were selected spread over repeats 1, 3, 4, 5, 6, 7, 9 and 10 respectively. Results: We found two SNP’s, rs17616434 (P 0.002) and rs2069772 (P 0.038), significantly associated with CMA. One is located near the toll like receptor 6 (TLR6)= gene, which functionally= interacts with toll-like receptor 2, and is associated with an increased risk of other allergic diseases. One is located at the Interleukin 2 (IL2) locus. Twelve FLG amplicons were analyzed, but showed no significant enrichment. -
Download Download
Supplementary Figure S1. Results of flow cytometry analysis, performed to estimate CD34 positivity, after immunomagnetic separation in two different experiments. As monoclonal antibody for labeling the sample, the fluorescein isothiocyanate (FITC)- conjugated mouse anti-human CD34 MoAb (Mylteni) was used. Briefly, cell samples were incubated in the presence of the indicated MoAbs, at the proper dilution, in PBS containing 5% FCS and 1% Fc receptor (FcR) blocking reagent (Miltenyi) for 30 min at 4 C. Cells were then washed twice, resuspended with PBS and analyzed by a Coulter Epics XL (Coulter Electronics Inc., Hialeah, FL, USA) flow cytometer. only use Non-commercial 1 Supplementary Table S1. Complete list of the datasets used in this study and their sources. GEO Total samples Geo selected GEO accession of used Platform Reference series in series samples samples GSM142565 GSM142566 GSM142567 GSM142568 GSE6146 HG-U133A 14 8 - GSM142569 GSM142571 GSM142572 GSM142574 GSM51391 GSM51392 GSE2666 HG-U133A 36 4 1 GSM51393 GSM51394 only GSM321583 GSE12803 HG-U133A 20 3 GSM321584 2 GSM321585 use Promyelocytes_1 Promyelocytes_2 Promyelocytes_3 Promyelocytes_4 HG-U133A 8 8 3 GSE64282 Promyelocytes_5 Promyelocytes_6 Promyelocytes_7 Promyelocytes_8 Non-commercial 2 Supplementary Table S2. Chromosomal regions up-regulated in CD34+ samples as identified by the LAP procedure with the two-class statistics coded in the PREDA R package and an FDR threshold of 0.5. Functional enrichment analysis has been performed using DAVID (http://david.abcc.ncifcrf.gov/) -
A Cross-Laboratory Database of Brain Cell-Type Expression Profiles with Applications to Marker Gene Identification and Bulk Brain Tissue Transcriptome Interpretation
bioRxiv preprint doi: https://doi.org/10.1101/089219; this version posted November 22, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. NeuroExpresso: A cross-laboratory database of brain cell-type expression profiles with applications to marker gene identification and bulk brain tissue transcriptome interpretation B. Ogan Mancarci1,2,3, Lilah Toker2,3, Shreejoy Tripathy2,3, Brenna Li2,3, Brad Rocco4,5, Etienne Sibille4,5, Paul Pavlidis2,3* 1Graduate Program in Bioinformatics, University of British Columbia, Vancouver, Canada 2Department of Psychiatry, University of British Columbia, Vancouver, Canada 3Michael Smith Laboratories, University of British Columbia, Vancouver, Canada 4Campbell Family Mental Health Research Institute of CAMH 5Department of Psychiatry and the Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada. Address correspondence to; Paul Pavlidis, PhD 177 Michael Smith Laboratories 2185 East Mall University of British Columbia Vancouver BC V6T1Z4 604 827 4157 [email protected] Ogan Mancarci: [email protected] Lilah Toker: [email protected] Shreejoy Tripathy: [email protected] Brenna Li: [email protected] Brad Rocco: [email protected] Etienne Sibille: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/089219; this version posted November 22, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
Early Pregnancy Vitamin D Status and Risk of Preeclampsia
Early pregnancy vitamin D status and risk of preeclampsia Hooman Mirzakhani, … , Joseph Loscalzo, Scott T. Weiss J Clin Invest. 2016;126(12):4702-4715. https://doi.org/10.1172/JCI89031. Clinical Medicine Clinical trials Reproductive biology BACKGROUND. Low vitamin D status in pregnancy was proposed as a risk factor of preeclampsia. METHODS. We assessed the effect of vitamin D supplementation (4,400 vs. 400 IU/day), initiated early in pregnancy (10–18 weeks), on the development of preeclampsia. The effects of serum vitamin D (25-hydroxyvitamin D [25OHD]) levels on preeclampsia incidence at trial entry and in the third trimester (32–38 weeks) were studied. We also conducted a nested case-control study of 157 women to investigate peripheral blood vitamin D–associated gene expression profiles at 10 to 18 weeks in 47 participants who developed preeclampsia. RESULTS. Of 881 women randomized, outcome data were available for 816, with 67 (8.2%) developing preeclampsia. There was no significant difference between treatment (N = 408) or control (N = 408) groups in the incidence of preeclampsia (8.08% vs. 8.33%, respectively; relative risk: 0.97; 95% CI, 0.61–1.53). However, in a cohort analysis and after adjustment for confounders, a significant effect of sufficient vitamin D status (25OHD ≥30 ng/ml) was observed in both early and late pregnancy compared with insufficient levels (25OHD <30 ng/ml) (adjusted odds ratio, 0.28; 95% CI, 0.10–0.96). Differential expression of 348 vitamin D–associated […] Find the latest version: https://jci.me/89031/pdf CLINICAL MEDICINE The Journal of Clinical Investigation Early pregnancy vitamin D status and risk of preeclampsia Hooman Mirzakhani,1 Augusto A. -
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
Independent Centromere Formation in a Capricious, Gene-Free Domain of Chromosome 13Q21 in Old World Monkeys and Pigs
Open Access Research2006CardoneetVolume al. 7, Issue 10, Article R91 Independent centromere formation in a capricious, gene-free comment domain of chromosome 13q21 in Old World monkeys and pigs Maria Francesca Cardone*, Alicia Alonso†, Michele Pazienza*, Mario Ventura*, Gabriella Montemurro*, Lucia Carbone*, Pieter J de Jong‡, Roscoe Stanyon§, Pietro D'Addabbo*, Nicoletta Archidiacono*, Xinwei She¶, Evan E Eichler¶, Peter E Warburton† and Mariano Rocchi* reviews Addresses: *Department of Genetics and Microbiology, University of Bari, Bari, Italy. †Department of Human Genetics, Mount Sinai School of Medicine, New York, New York 10029, USA. ‡Children's Hospital Oakland Research Institute, Oakland, California 94609, USA. §Department of Animal Biology and Genetics 'Leo Pardi', University of Florence, Florence, Italy. ¶Howard Hughes Medical Institute, Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195, USA. Correspondence: Mariano Rocchi. Email: [email protected] Published: 13 October 2006 Received: 3 May 2006 reports Revised: 31 July 2006 Genome Biology 2006, 7:R91 (doi:10.1186/gb-2006-7-10-r91) Accepted: 13 October 2006 The electronic version of this article is the complete one and can be found online at http://genomebiology.com/2006/7/10/R91 © 2006 Cardone et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which deposited research permits unrestricted -
Hippo and Sonic Hedgehog Signalling Pathway Modulation of Human Urothelial Tissue Homeostasis
Hippo and Sonic Hedgehog signalling pathway modulation of human urothelial tissue homeostasis Thomas Crighton PhD University of York Department of Biology November 2020 Abstract The urinary tract is lined by a barrier-forming, mitotically-quiescent urothelium, which retains the ability to regenerate following injury. Regulation of tissue homeostasis by Hippo and Sonic Hedgehog signalling has previously been implicated in various mammalian epithelia, but limited evidence exists as to their role in adult human urothelial physiology. Focussing on the Hippo pathway, the aims of this thesis were to characterise expression of said pathways in urothelium, determine what role the pathways have in regulating urothelial phenotype, and investigate whether the pathways are implicated in muscle-invasive bladder cancer (MIBC). These aims were assessed using a cell culture paradigm of Normal Human Urothelial (NHU) cells that can be manipulated in vitro to represent different differentiated phenotypes, alongside MIBC cell lines and The Cancer Genome Atlas resource. Transcriptomic analysis of NHU cells identified a significant induction of VGLL1, a poorly understood regulator of Hippo signalling, in differentiated cells. Activation of upstream transcription factors PPARγ and GATA3 and/or blockade of active EGFR/RAS/RAF/MEK/ERK signalling were identified as mechanisms which induce VGLL1 expression in NHU cells. Ectopic overexpression of VGLL1 in undifferentiated NHU cells and MIBC cell line T24 resulted in significantly reduced proliferation. Conversely, knockdown of VGLL1 in differentiated NHU cells significantly reduced barrier tightness in an unwounded state, while inhibiting regeneration and increasing cell cycle activation in scratch-wounded cultures. A signalling pathway previously observed to be inhibited by VGLL1 function, YAP/TAZ, was unaffected by VGLL1 manipulation. -
Genetic Network Analysis of Human CD34+ Hematopoietic Stem
■ ORIGINAL ARTICLE ■ + GENETIC NETWORK ANALYSIS OF HUMAN CD34 HEMATOPOIETIC STEM/PRECURSOR CELLS Shing-Jyh Chang1,2, Tse-Sung Huang3, Kung-Liahng Wang4,5,6, Tao-Yeuan Wang7, Yuh-Cheng Yang4, Margaret Dah-Tsyr Chang2, Yu-Hsuan Wu3, Hsei-Wei Wang3,8,9,10* 1Department of Obstetrics and Gynecology, Mackay Memorial Hospital, 2National Tsing Hua University, HsinChu, 3Institute of Microbiology and Immunology, National Yang-Ming University, 4Department of Obstetrics and Gynecology, Mackay Memorial Hospital, 5National Taipei College of Nursing, 6Mackay Medicine, Nursing and Management College, 7Department of Pathology, Mackay Memorial Hospital, 8Institute of Clinical Medicine and 9VGH-YM Genome Center, National Yang-Ming University, and 10Department of Education and Research, Taipei City Hospital, Taipei, Taiwan. SUMMARY Objective: Somatic CD34+ hematopoietic stem/precursor cells (HSPCs) give rise to hematopoietic cells and endothelial cells and have been used in clinical applications. Understanding the genes responsible for stemness and how they interact with each other will help us to manipulate these cells more efficiently in the future. Materials and Methods: We performed microarray analysis on human CD34+ HSPCs and on two different progeny cell types, i.e. microvascular endothelial cells and peripheral blood mononuclear cells. Systems biology and advanced bioinformatics tools were used to help clarify the genetic networks associated with these stem cell genes. Results: We identified CD34+ HSPC genes and found that they were involved in critical biologic processes such as cell cycle regulation, chromosome organization, and DNA repair. We also identified a novel precursor gene cluster on chromosome 19p13.3. Analysis of HSPC-enriched genes using systems biology tools revealed a com- plex genetic network functioning in CD34+ cells, in which several genes acted as hubs to maintain the stability (such as GATA1) or connectivity (such as hepatic growth factor) of the whole network. -
UNDERSTANDING the BRAIN Tbook Collections
FROM THE NEW YORK TIMES ARCHIVES UNDERSTANDING THE BRAIN TBook Collections Copyright © 2015 The New York Times Company. All rights reserved. Cover Photograph by Zach Wise for The New York Times This ebook was created using Vook. All of the articles in this work originally appeared in The New York Times. eISBN: 9781508000877 The New York Times Company New York, NY www.nytimes.com www.nytimes.com/tbooks Obama Seeking to Boost Study of Human Brain By JOHN MARKOFF FEB. 17, 2013 The Obama administration is planning a decade-long scientific effort to examine the workings of the human brain and build a comprehensive map of its activity, seeking to do for the brain what the Human Genome Project did for genetics. The project, which the administration has been looking to unveil as early as March, will include federal agencies, private foundations and teams of neuroscientists and nanoscientists in a concerted effort to advance the knowledge of the brain’s billions of neurons and gain greater insights into perception, actions and, ultimately, consciousness. Scientists with the highest hopes for the project also see it as a way to develop the technology essential to understanding diseases like Alzheimer’sand Parkinson’s, as well as to find new therapies for a variety of mental illnesses. Moreover, the project holds the potential of paving the way for advances in artificial intelligence. The project, which could ultimately cost billions of dollars, is expected to be part of the president’s budget proposal next month. And, four scientists and representatives of research institutions said they had participated in planning for what is being called the Brain Activity Map project. -
From the Neuron Doctrine to Neural Networks
LINK TO ORIGINAL ARTICLE LINK TO INITIAL CORRESPONDENCE other hand, one of my mentors, David Tank, argued that for a true understanding of a On testing neural network models neural circuit we should be able to actu- ally build it, which is a stricter definition Rafael Yuste of a successful theory (D. Tank, personal communication) Finally, as mentioned in In my recent Timeline article, I described existing neural network models have enough the Timeline article, one will also need to the emergence of neural network models predictive value to be considered valid or connect neural network models to theories as an important paradigm in neuroscience useful for explaining brain circuits.” (REF. 1)). and facts at the structural and biophysical research (From the neuron doctrine to neu- There are many exciting areas of progress levels of neural circuits and to those in cog- ral networks. Nat. Rev. Neurosci. 16, 487–497 in current neuroscience detailing phenom- nitive sciences as well, for proper ‘scientific (2015))1. In his correspondence (Neural enology that is consistent with some neural knowledge’ to occur in the Kantian sense. networks in the future of neuroscience network models, some of which I tried to research. Nat. Rev. Neurosci. http://dx.doi. summarize and illustrate, but at the same Rafael Yuste is at the Neurotechnology Center and org/10.1038/nrn4042 (2015))2, Rubinov time we are still far from a rigorous demon- Kavli Institute of Brain Sciences, Departments of provides some thoughtful comments about stration of any neural network model with Biological Sciences and Neuroscience, Columbia University, New York, New York 10027, USA. -
Cross-Laboratory Analysis of Brain Cell Type Transcriptomes with Applications to Interpretation of Bulk Tissue Data
Methods/New Tools Novel Tools and Methods Cross-Laboratory Analysis of Brain Cell Type Transcriptomes with Applications to Interpretation of Bulk Tissue Data B. Ogan Mancarci,1,2,3 Lilah Toker,2,3 Shreejoy J. Tripathy,2,3 Brenna Li,2,3 Brad Rocco,4,5 Etienne Sibille,4,5 and Paul Pavlidis2,3 DOI:http://dx.doi.org/10.1523/ENEURO.0212-17.2017 1Graduate Program in Bioinformatics, University of British Columbia, Vancouver V6T 1Z4, Canada, 2Department of Psychiatry, University of British Columbia, Vancouver V6T 2A1, Canada, 3Michael Smith Laboratories, University of British Columbia, Vancouver V6T 1Z4, Canada, 4Campbell Family Mental Health Research Institute of CAMH, and 5Department of Psychiatry and the Department of Pharmacology and Toxicology, University of Toronto, Vancouver M5S 1A8, Canada Visual Abstract November/December 2017, 4(6) e0212-17.2017 1–20 Methods/New Tools 2 of 20 Significance Statement Cell type markers are powerful tools in the study of the nervous system that help reveal properties of cell types and acquire additional information from large scale expression experiments. Despite their usefulness in the field, known marker genes for brain cell types are few in number. We present NeuroExpresso, a database of brain cell type-specific gene expression profiles, and demonstrate the use of marker genes for acquiring cell type-specific information from whole tissue expression. The database will prove itself as a useful resource for researchers aiming to reveal novel properties of the cell types and aid both laboratory and computational scientists to unravel the cell type-specific components of brain disorders. Establishing the molecular diversity of cell types is crucial for the study of the nervous system.